Role of cytochrome B5 in modulating peroxide-supported CYP3A4 activity: Evidence for a conformational transition and cytochrome P450 heterogeneity

Drug Metabolism and Disposition

Volumn 33, Issue 8, 2005, Pages 1131-1136

  Kumar, Santosh ^a   Davydov, Dmitri R ^a   Halpert, James R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME B5; CYTOCHROME P450 3A4; 7 BENZYLOXYQUINOLINE; 7-BENZYLOXYQUINOLINE; ALPHA-NAPHTHOFLAVONE; BENZOFLAVONE DERIVATIVE; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; ENZYME ACTIVATOR; HEME; HYDROGEN PEROXIDE; QUINOLINE DERIVATIVE; RECOMBINANT PROTEIN;

ALLOSTERISM; AMINO ACID ANALYSIS; ANIMAL CELL; ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE LOCATION; KINETICS; NONHUMAN; OXIDATION; PREDICTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; STANDARDIZATION; SUBSTITUTION REACTION; WILD TYPE; ANIMAL; BINDING SITE; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; GENETICS; IN VITRO STUDY; METABOLISM; OXIDATION REDUCTION REACTION;

ALLOSTERIC REGULATION; ANIMALS; BENZOFLAVONES; BINDING SITES; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATORS; HEME; HYDROGEN PEROXIDE; KINETICS; OXIDATION-REDUCTION; QUINOLINES; RATS; RECOMBINANT PROTEINS;

EID: 22944450062     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.105.004606     Document Type: Article

References (38)

1. 5 and cytochrome P450 reductase. J Biol Chem 273:17036-17049.
2. 5 in stimulating cytochrome P4502B4 catalysis. J Biol Chem 279:36809-36818.
3. Davydov DR, Deprez E, Hoa GH, Knyushko TV, Kuznetsova GP, Koen YM, and Archakov AI (1995) High-pressure-induced transitions in microsomal cytochrome P450 2B4 in solution: evidence for conformational inhomogeneity in the oligomers. Arch Biochem Biophys 320:330-344.
4. Davydov DR and Halpert JR (2004) Allosteric mechanisms in cytochrome P450: conformational transition in CYP3A4 caused by the binding of α-naphthoflavone. FASEB J 18:C-178.
5. Davydov DR, Halpert JR, Renaud JP, and Hui Bon Hoa G (2003) Conformational heterogeneity of cytochrome P450 3A4 revealed by high pressure spectroscopy. Biochem Biophys Res Commun 312:121-130.
6. Domanski TL, He YA, Harlow GR, and Halpert JR (2000) Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. J Pharmacol Exp Ther 293:585-591.
7. Domanski TL, He YA, Khan KK, Roussel F, Wang Q, and Halpert JR (2001) Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 40:10150-10160.
8. Guengerich FP (1999) Cytochrome P450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
9. Guryev OL, Gilep AA, Usanov SA, and Estabrook RW (2001) Interaction of apo-cytochromes P450 3A4 and P450 17A: relevance of heme transfer reactions. Biochemistry 40:5018-5031.
10. Harlow GR and Halpert JR (1997) Alanine-scanning mutagenesis of putative substrate recognition sites in human cytochrome P4503A4. J Biol Chem 272:5396-5402.
11. Harlow GR and Halpert JR (1998) Analysis of human cytochrome P4503A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci USA 95:6636-6641.
12. He YA, Roussel F, and Halpert JR (2003) Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. Arch Biochem Biophys 409:92-101.
13. Hutzler JM and Tracy TS (2002) Atypical kinetic problems in drug metabolism reactions. Drug Metab Dispos 30:355-362.
14. 5 with four cytochrome P450 enzymes from the untreated rat. Drug Metab Dispos 13:453-458.
15. Khan KK and Halpert JR (2002) 7-Benzyloxyquinoline oxidation by P450eryF A245T: finding of a new fluorescent substrate probe. Chem Res Toxicol 15:806-814.
16. Khan KK, Liu H, and Halpert JR (2003) Homotropic versus heterotropic cooperativity of cytochrome P450eryF: a substrate oxidation and spectral titration study. Drug Metab Dispos 31:356-359.
17. Koley AP, Buters JT, Robinson RC, Markowitz A, and Friedman FK (1995) CO binding kinetics of human cytochrome P450 3A4: specific interaction of substrates with kinetically distinguishable conformers. J Biol Chem 270:5014-5018.
18. Kumar S, Chen CS, Waxman DJ, and Halpert JR (2005) Directed evolution of mammalian cytochrome P450 2B1: mutations outside of the active site enhance the metabolism of several substrates including the anticancer prodrugs cyclophosphamide and ifosfamide. J Biol Chem 280:19569-19575.
19. Nebert DW and Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360:1155-1162.
20. scc with hemin activated with Woodward's reagent K. J Biol Chem 267:1438-1442.
21. 5. J Inorg Biochem 93:152-160.
22. 5 on the interaction between cytochrome P450 2B4 and P450 reductase. J Inorg Biochem 97:265-273.
23. Renaud JP, Davydov DR, Heirwegh KP, Mansuy D, and Hui Bon Hoa G (1996) Thermodynamic studies of substrate binding and spin transition in human cytochrome P450 3A4 expressed in yeast microsomes. Biochem J 319:675-681.
24. 5. Drug Metab Rev 31:351-364.
25. 5. Pharmacol Ther 97:139-152.
26. Segel IH (1993) Kinetic behavior at high enzyme concentrations, in Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems (Segel IH ed) pp 72-75, Wiley Classic Library, New York.
27. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, and Korzekwa KR (1994) Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
28. 5 binding to the terminal hemo-protein. J Biol Chem 258:13444-13452.
29. Tracy TS (2003) Atypical enzyme kinetics: their effect on in vitro-in vivo pharmacokinetic predictions and drug interactions. Curr Drug Metab 4:341-346.
30. Ueng YF, Kuwabara T, Chun YJ, and Guengerich PF (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-380.
31. Uvarov VY, Tretiakov VE, and Archakov AI (1990) Heme maintains catalytically active structure of cytochrome P450. FEBS Lett 260:309-312.
32. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science (Wash DC) 305:683-686.
33. 5 and NADPH-cytochrome P450 reductase in proteoliposomes. Biochemistry 34:10113-10119.
34. 5 and of site-directed mutagenesis. Drug Metab Dispos 32:155-161.
35. 5 on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol 66:2333-2340.
36. 5. J Biol Chem 271:27438-27444.
37. 5 or heme oxygenase. J Biol Chem 276:30885-30891.
38. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-angstrom resolution. J Biol Chem 279:38091-38094.